Cases Center

At NeoTrident, we provide cutting-edge solutions to enable researchers to focus on groundbreaking science.

Latest Updates

Stay informed with real-time news and insights about NeoTrident and our advancements.

#image_title

Zhejiang Brilliant Optoelectronic Technology Co., Ltd.: Accelerating R&D with Digital Solutions

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.

#image_title

Shanghai Huayi Group: Driving Digital Transformation in Chemical R&D

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.

#image_title

Ningbo Topcentral: Advancing Sustainable Materials with Digital R&D Innovation

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.

#image_title

Chambroad Group: Pioneering Digital R&D Transformation for the Chemical Industry

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.

#image_title

Guangzhou Tinci Materials Technology Co., Ltd.: Enhancing R&D Efficiency with Digital Solutions

Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.

Shopping Basket